SA
PRME icon

Scarborough Advisors’s Prime Medicine PRME Stock Holding History

Scarborough Advisors’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,258
Closed -$4.38K – 541
2026
Q1 		$4.38K Buy
1,258
+1
+0.1% +$4 ﹤0.01% 533
2025
Q4 		$4.36K Buy
1,257
+752
+149% +$3.35K ﹤0.01% 321
2025
Q3 		$2.8K Buy
+505
New +$2.05K ﹤0.01% 343

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Scarborough Advisors's PRME Position: Q2 2026 in Review

Scarborough Advisors sold out of Prime Medicine (PRME) in Q2 2026, closing a stake of 1,258 shares — an estimated $4.38K sold.

Scarborough Advisors first reported a position in PRME in Q3 2025 and held it in 3 quarters. The position peaked at $4.38K in Q1 2026. 188 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Scarborough Advisors reported no remaining Prime Medicine position as of Q2 2026 after selling out during the quarter.
  • Scarborough Advisors sold 1,258 Prime Medicine shares in Q2 2026, an estimated $4.38K.
  • Scarborough Advisors first reported a position in Prime Medicine in Q3 2025 and held it in 3 quarters.
  • Scarborough Advisors's Prime Medicine position peaked at $4.38K in Q1 2026.
  • 188 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Scarborough Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.